ACADIA Pharmaceuticals (ACAD) : March Altus Capital Management Lp reduced its stake in ACADIA Pharmaceuticals by 27.68% during the most recent quarter end. The investment management company now holds a total of 21,552 shares of ACADIA Pharmaceuticals which is valued at $605,827 after selling 8,249 shares in ACADIA Pharmaceuticals , the firm said in a disclosure report filed with the SEC on May 12, 2016.ACADIA Pharmaceuticals makes up approximately 6.10% of March Altus Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Hap Trading added ACAD to its portfolio by purchasing 49,430 company shares during the most recent quarter which is valued at $1.4 Million. ACADIA Pharmaceuticals makes up approx 0.16% of Hap Trading’s portfolio.Blackrock Fund Advisors boosted its stake in ACAD in the latest quarter, The investment management firm added 349,519 additional shares and now holds a total of 3,549,078 shares of ACADIA Pharmaceuticals which is valued at $99.8 Million. ACADIA Pharmaceuticals makes up approx 0.02% of Blackrock Fund Advisors’s portfolio. Ft Options added ACAD to its portfolio by purchasing 108 company shares during the most recent quarter which is valued at $3,036. ACADIA Pharmaceuticals makes up approx 0.01% of Ft Options’s portfolio.Gilder Gagnon Howe Co reduced its stake in ACAD by selling 134,363 shares or 96.64% in the most recent quarter. The Hedge Fund company now holds 4,671 shares of ACAD which is valued at $129,153.American Century Companies Inc boosted its stake in ACAD in the latest quarter, The investment management firm added 13,152 additional shares and now holds a total of 85,356 shares of ACADIA Pharmaceuticals which is valued at $2.4 Million.
ACADIA Pharmaceuticals opened for trading at $32.98 and hit $34.1336 on the upside on Friday, eventually ending the session at $34.04, with a gain of 3.65% or 1.2 points. The heightened volatility saw the trading volume jump to 31,47,681 shares. Company has a market cap of $3,852,069 M.
On the company’s financial health, ACADIA Pharmaceuticals reported $-0.45 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-0.42.Analysts expectations of $ .22.During the same quarter in the previous year, the company posted $-0.40 EPS.
Many Wall Street Analysts have commented on ACADIA Pharmaceuticals. ACADIA Pharmaceuticals was Downgraded by Leerink Partners to ” Mkt Perform” on May 3, 2016. Company shares were Reiterated by Piper Jaffray on Mar 30, 2016 to “Overweight”, Firm has raised the Price Target to $ 44 from a previous price target of $39 .
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis Alzheimers disease psychosis Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan has discovered and engaged in the development of small-molecule product candidates such as alpha adrenergic agonists and muscarinic receptors.